Investing Profile

Peter Keen

Angel
Independent Investment Committee member at British Patient Capital (Direct Investments)
Cambridge, Massachusetts
Photo of Peter Keen, Angel
cb
Angel
$5K - $50K
$25K
4
CompanyStageDateRound SizeTotal Raised
SupaPass
SeedMar 2020$620K
SeedDec 2015$650K
SeedNov 2014$920K
$2.2M
Small Pharma
SeedApr 2017$1M
$1M
£830K
Co-investors: Ken Belotsky (Negev Capital), David Ebsworth
Independent Investment Committee member British Patient Capital (Direct Investments)2021 - Present
Non Executive Director Endomagnetics Limited2017 - Present
Board of Trustees LifeArc (formerly MRC Technology)2013 - 2021
Non Executive Director SpringWorks Therapeutics2017 - 2019
Non Executive Director Biotech Growth Trust PLC1997 - 2017
Non Executive Director Congenica Ltd2014 - 2016
CEO/Executive Director Cambridge Innovation Capital plc2013 - 2016
Senior Independent Director Abcam PLC2005 - 2014
Member of Supervisory Board Kiadis Pharma2012 - 2013
Venture Partner DFJ Esprit LLP2012 - 2013
Non Executive Director Horizon Discovery Ltd2011 - 2013
Non Executive Director Q Chip Ltd2011 - 2013
Chairman Oval Medical Technologies Limited2010 - 2013
Non Executive Director Ark Therapeutics PLC1998 - 2012
Chairman Exosect Limited2010 - 2011
Corporate Development and Finance Director Serentis Ltd2007 - 2010
Partner DFJ Esprit LLP2006 - 2007
Chief Financial Officer Arakis Ltd2004 - 2006
UK Managing Director/Consultant Merlin Biosciences1996 - 2004
University of Hull BSc (Econ) Economics and Accountancy